Literature DB >> 15153757

Fractalkine and its receptor, CX3CR1, upregulation in streptozotocin-induced diabetic kidneys.

Yuichi Kikuchi1, Ryota Ikee, Noriaki Hemmi, Naomi Hyodo, Takamitsu Saigusa, Tamehachi Namikoshi, Muneharu Yamada, Shigenobu Suzuki, Soichiro Miura.   

Abstract

BACKGROUND: Fractalkine is induced on activated endothelial cells and promotes strong adhesion of T cells and monocytes via its receptor CX3CR1. In kidney, fractalkine expression might be induced by high shear stress and play an important role in prolonged glomerular diseases. We examined whether fractalkine and CX3CR1 upregulation are found in streptozotocin-induced diabetic kidneys.
METHODS: Diabetic rats were randomized to receive an angiotensin-converting enzyme inhibitor (temocapril), aminoguanidine or no treatment. Reverse transcription-competitive polymerase chain reaction, Western blot analysis and immunohistochemistry were used.
RESULTS: At 4 weeks, fractalkine and CX3CR1 mRNA expression in diabetic kidneys increased compared with that in controls. Fractalkine staining in diabetic kidneys was clearly detected, along with glomerular capillary lumen and peritubular capillaries. A few CX3CR1 positive cell infiltration in diabetic glomeruli were found. Treatment with temocapril or aminoguanidine did not affect these changes. At 8 weeks, fractalkine and CX3CR1 mRNA expression in untreated diabetic kidneys markedly increased compared with that in controls. Membrane-anchored fractalkine protein expression in untreated diabetic rats also increased. The increased expression was suppressed by the treatment with temocapril and aminoguanidine. Increased CX3CR1-positive cell infiltration in diabetic glomeruli was also inhibited by both treatments. Some CX3CR1-positive cells were ED3 positive.
CONCLUSIONS: Fractalkine and CX3CR1 upregulation were demonstrated in an early stage of diabetic kidney. These upregulation, as well as urinary albumin excretion, were suppressed by treatments with temocapril and aminoguanidine for 8 weeks. These findings suggest that fractalkine expression and CX3CR1-positive cell infiltration in diabetic kidneys might play an important role for progression of diabetic nephropathy. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15153757     DOI: 10.1159/000077594

Source DB:  PubMed          Journal:  Nephron Exp Nephrol        ISSN: 1660-2129


  16 in total

1.  Microarray analysis reveals novel gene expression changes associated with erectile dysfunction in diabetic rats.

Authors:  Chris J Sullivan; Thomas H Teal; Ian P Luttrell; Khoa B Tran; Mette A Peters; Hunter Wessells
Journal:  Physiol Genomics       Date:  2005-08-23       Impact factor: 3.107

Review 2.  New molecular insights in diabetic nephropathy.

Authors:  Ionel Alexandru Checheriţă; Gina Manda; Mihai Eugen Hinescu; Ileana Peride; Andrei Niculae; Ştefana Bîlha; Angelica Grămăticu; Luminiţa Voroneanu; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

3.  Anti-inflammatory Action of Metformin with Respect to CX3CL1/CX3CR1 Signaling in Human Placental Circulation in Normal-Glucose Versus High-Glucose Environments.

Authors:  D Szukiewicz; Grzegorz Szewczyk; Michal Pyzlak; Aleksandra Stangret; Michal Bachanek; Seweryn Trojanowski; Habib Alkhalayla; Jaroslaw Wejman
Journal:  Inflammation       Date:  2018-12       Impact factor: 4.092

Review 4.  Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets.

Authors:  Raimund Pichler; Maryam Afkarian; Brad P Dieter; Katherine R Tuttle
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-24

Review 5.  Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.

Authors:  Juan F Navarro-González; Carmen Mora-Fernández; Mercedes Muros de Fuentes; Javier García-Pérez
Journal:  Nat Rev Nephrol       Date:  2011-05-03       Impact factor: 28.314

Review 6.  Endothelial cells: potential novel regulators of renal inflammation.

Authors:  Jim C Oates; Dayvia L Russell; Justin P Van Beusecum
Journal:  Am J Physiol Renal Physiol       Date:  2022-02-07

Review 7.  Diabetic nephropathy--emerging epigenetic mechanisms.

Authors:  Mitsuo Kato; Rama Natarajan
Journal:  Nat Rev Nephrol       Date:  2014-07-08       Impact factor: 28.314

8.  Associations of fractalkine receptor (CX3CR1) and CCR5 gene variants with hypertension, diabetes and atherosclerosis in chronic renal failure patients undergoing hemodialysis.

Authors:  Binnur Bagci; Gokhan Bagci; Can Huzmeli; Ilhan Sezgin; Ozturk Ozdemir
Journal:  Int Urol Nephrol       Date:  2016-04-27       Impact factor: 2.370

Review 9.  Regulation of Monocytes/Macrophages by the Renin-Angiotensin System in Diabetic Nephropathy: State of the Art and Results of a Pilot Study.

Authors:  Claudine Moratal; Audrey Laurain; Mourad Naïmi; Thibault Florin; Vincent Esnault; Jaap G Neels; Nicolas Chevalier; Giulia Chinetti; Guillaume Favre
Journal:  Int J Mol Sci       Date:  2021-06-02       Impact factor: 5.923

10.  Suppression of Inflammatory Cardiac Cytokine Network in Rats with Untreated Obesity and Pre-Diabetes by AT2 Receptor Agonist NP-6A4.

Authors:  Madhavi P Gavini; Abuzar Mahmood; Anthony M Belenchia; Paige Beauparlant; Senthil A Kumar; Sivakumar Ardhanari; Vincent G DeMarco; Lakshmi Pulakat
Journal:  Front Pharmacol       Date:  2021-06-18       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.